Foley Partner Courtenay Brinckerhoff was quoted in an article that appeared in the June 30, 2010 issue of Managing Intellectual Property titled “Federal Circuit to re-hear biotech cases post-Bilski.” Brinckerhoff discusses the Supreme Court’s decision to grant certiorari, and then vacate and remand biotech patent case Prometheus v Mayo in light of the decision issued in Bilski v. Kappos. She states that the contested patents in Prometheus should survive since the Federal Circuit has already found that they meet the machine-or-transformation test, but notes that the Bilski decision includes some troubling points for biotech and pharmaceutical patents. She adds that assessing whether a particular patent might promote or impede innovation as a way of determining patent eligibility could be a slippery slope.
People
Related News
12 May 2025
In the News
Judith Waltz Comments on Provider Settlement After Self-Disclosure
Foley & Lardner LLP partner Judith Waltz commented on a recent settlement by a provider with the U.S. Department of Health and Human Services Office of Inspector General (OIG) in the Report on Medicare Compliance article, "After Self-Disclosure, Provider Settles Case Over Failure to Report, Return Overpayments."
12 May 2025
In the News
Foley's Digital Infrastructure Arrivals Featured Across Legal Press
Foley & Lardner LLP partners Daniel Farris and Joe McClendon are featured in legal press for their arrival to the firm.
07 May 2025
In the News
Foley Attorneys Featured in Q&A on CPSC Oversight of Cosmetics Industry
Foley & Lardner LLP attorneys Erik Swanholt, Kristin McGaver, and Mikaela Mitchum are featured in a Cosmetics Design Q&A on what industry brands need to know regarding oversight from the U.S. Consumer Product Safety Commission.